Pacira Q4 Revenues Rise 5% to $196.9M, Adjusted EBITDA Hits $38.7M
Pacira BioSciences delivered fourth quarter revenues of $196.9M (up 5% year-on-year) and full-year revenues of $726.4M driven by a 7% volume increase in EXPAREL sales. Adjusted EBITDA reached $38.7M in Q4 and $186.5M for 2025 while the company repurchased 5.9M shares for $150M, reinforcing capital return strategy.
1. Fourth Quarter and Full-Year Financial Results
Pacira reported Q4 revenues of $196.9M, a 5% increase over Q4 2024, and full-year 2025 revenues of $726.4M. EXPAREL net product sales rose by 5% to $155.8M in Q4, ZILRETTA sales held at $33.0M, and iovera° sales increased 8% to $7.0M. GAAP net income was $1.6M ($0.04/share) in Q4 and $7.0M ($0.16/share) for the year, while non-GAAP net income was $24.4M ($0.58/share) in Q4 and $44.3M ($0.96/share) a year ago.
2. Share Repurchase Program
In Q4 the company repurchased 2.0M shares at an average price of $24.94 for $50.0M, bringing total 2025 repurchases to 5.9M shares for $150.0M. This reflects management’s commitment to capital return amid strong cash generation, with year-end cash and investments of $238.4M.
3. Strategic Partnership with LG Chem
Pacira entered an exclusive agreement granting LG Chem rights to commercialize EXPAREL in select Asia-Pacific markets. Under the deal, Pacira received an upfront payment, will supply product at a transfer price and earn tiered royalties, with LG Chem planning marketing authorizations in South Korea and Thailand in 2026.
4. Board Appointment
In January 2026, Samit Hirawat, M.D., former Chief Medical Officer and Head of Global Drug Development at Bristol Myers Squibb, was appointed to Pacira’s Board, increasing its size to 10 members and adding over 25 years of clinical development and industry expertise.